UBS Reaffirms Their Buy Rating on ALS (CPBLF)

UBS analyst Nathan Reilly maintained a Buy rating on ALS (CPBLF – Research Report) today and set a price target of A$18.70. The company's shares closed last Thursday at $9.53.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
According to TipRanks, Reilly is ranked #1423 out of 9371 analysts.
ALS has an analyst consensus of Strong Buy, with a price target consensus of $11.01.
CPBLF market cap is currently $4.87B and has a P/E ratio of 929.09.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Bloomberg

4 hours ago

• Bloomberg

Montage Is Said to Hire Banks for $1 Billion Hong Kong Listing

Chinese chip designer Montage Technology Co. has hired banks for its planned Hong Kong listing that could raise about $1 billion, according to people familiar with the matter. The Shanghai-listed company is working with China International Capital Corp., Morgan Stanley and UBS Group AG on the potential share sale, the people said, asking not to be identified because the information isn't public.

Business Insider

5 hours ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

5 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>